Aligos Therapeutics (ALGS)

• Market cap: $34.6M
• 1 day: -3.45%
• 5 days: -3.62%
• 1 month: -6.37%
• 3 months: -19.8%
• 6 months: -39.89%
• Year to date: -38.77%
• 1 year: -2.61%
• 5 years: -99.2%
• 10 years: -98.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Employees: 82